Skip to main content
TipRanks
Go Ultimate75% OFF

Balchem (BL9B) Q3 2026 Earnings Report

1 Followers

DE:BL9B Q3 2026 EPS Results

Actual EPS
EUR 1.30
Consensus EPS
EUR 1.27
Beat/Miss
Beat by +EUR 0.03
One Year Ago EPS
EUR 1.10

DE:BL9B Q3 2026 Revenue Results

Actual Revenue
EUR 258.26M
Expected Revenue
EUR 257.01M
Beat/Miss
Beat by +EUR 1.25M
YoY Revenue Growth
+8.63%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/23/2026
Time
Before Open
Conference Call
Friday, October 23, 2026
DE:BL9B Upcoming Earnings

Balchem's next earnings date is estimated for February 19, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:BL9B Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 23, 2026|% Change Since:2.32%|
Earnings Call Sentiment|Positive

The call was strongly positive, with record consolidated financial results, growth across all three segments, expanding gross margins, strong cash generation, balance-sheet improvement, continued product and science investment, and confidence in ongoing year-over-year growth. The company also cited challenges including higher input costs, elevated inventory, trade-practice circumvention, oil-price pressure, and normal fourth-quarter seasonality, but these were outweighed by the reported achievements and outlook.

Company Guidance

Balchem said it remains confident in its ability to deliver healthy growth over the long term and healthy year over year growth in the fourth quarter, although the fourth quarter is normally sequentially lower than the third quarter based on historic business seasonality; management expects to be finishing the year in that range of 22.5 to 23 for the effective tax rate, versus 22.7% year to date, and said it is contemplating another sports partnership or maybe 2, with 1 expected to be announced before our next earnings call, or in the next month or so.

  • Record Consolidated Quarterly ResultsBalchem reported record third-quarter consolidated revenue of $291 million, up 8.6% year over year; record GAAP earnings from operations of $62 million, up 14.4%; record consolidated net income of $47 million, up 16%; GAAP diluted EPS of $1.46, up 17.7%; record adjusted EBITDA of $80 million, up 12.4%; and record adjusted net earnings of $50 million, up 14.5%, or $1.57 per diluted share, up 16.3%.
  • Broad-Based Growth Across All SegmentsManagement reported healthy, broad-based growth across all three reporting segments, driven by market penetration of Balchem's specialty nutrients and delivery systems, favorable better-for-you trends in food and nutrition markets, and continued execution on strategic growth initiatives.
  • Positive Demand OutlookManagement said demand trends remain healthy across the majority of the business, with solid demand growth in human nutrition and health, continued adoption of nutrient technologies in animal nutrition and health, and healthy demand for specialized performance gases and services in specialty products. Management remains confident in Balchem's ability to deliver healthy long-term growth.
  • Human Nutrition and Health Delivered Record PerformanceHuman nutrition and health generated record sales of $188 million, up 8.1%, driven by growth in both the nutrients business and food ingredients and solutions businesses. Earnings from operations reached a record $46 million, up 11.8%, while adjusted earnings from operations reached a record $49 million, up 10.9%.
  • Animal Nutrition and Health AcceleratedAnimal nutrition and health sales were $63 million, up 11.7%, driven by higher sales in both monogastric and ruminant markets. Earnings from operations increased 82.8% to $6.8 million, and adjusted earnings from operations rose 73.6% to $7 million.
  • Animal Nutrition Technology Adoption and International GrowthGrowth in animal nutrition and health was supported by continued adoption of encapsulated rumen-protected nutrient technologies in dairy, pricing actions in the U.S. monogastric business, and gradual improvement in the European monogastric business following implementation of EU antidumping duties. Management also reported accelerated ruminant growth in Europe, the Middle East, and Asia.
  • Specialty Products Continued Profitable GrowthSpecialty products sales were $37 million, up 4.5%, driven by growth in performance gases. Earnings from operations increased 6.6% to $12 million, and adjusted earnings from operations rose 3% to $13 million. Management described the segment as delivering steady profitable growth.
  • Gross Margin ExpansionGross margin increased 10.7% to $106 million, and gross margin as a percentage of net sales expanded 70 basis points to 36.4%. The improvement was driven primarily by higher sales, favorable product mix, and manufacturing efficiencies.
  • Favorable Portfolio Mix TailwindsManagement said the higher-margin nutrition business within human nutrition and health is growing faster than the food business, while the higher-margin ruminant business within animal nutrition and health is growing faster than monogastric. Growth in the high-margin specialty products segment also provided a favorable portfolio mix tailwind.
  • Strong Cash Generation and Capital AllocationCash flow from operations was $70 million and free cash flow was $58 million. Balchem ended the quarter with $66 million of cash, repurchased approximately $28 million of common stock, and reduced net borrowings by $28 million.
  • Improved Balance Sheet and Financing CapacityNet leverage ended the quarter at 0.2x. Management said the expanded $650 million credit facility put in place in July positions the company to fund innovation, capacity expansion, and strategic acquisitions.
  • Lower Interest Expense and Stable Tax OutlookNet interest expense was $2 million, down $1 million from the prior year, reflecting lower outstanding borrowings and lower interest rates. Management expects to finish the year with an effective tax rate in the range of 22.5% to 23%, with year-to-date effective tax rate at 22.7%.
  • VitaCholine Cognitive Health ScienceA recently published MD Anderson-led pilot study in Alzheimer's and Dementia Translational Research and Clinical Interventions evaluated choline supplementation in cognitively healthy APOE4 carriers. Management said the findings provide encouraging new evidence supporting the potential role of VitaCholine in lifelong brain health, healthy aging, and cognition.
  • K2VITAL DELTA Cardiovascular StudyThe DANCODE trial, published in Circulation, examined Balchem's K2VITAL DELTA and coronary artery calcification and cardiovascular health. Management said the findings add important clinical evidence supporting vitamin K2's role in cardiovascular health and healthy aging and strengthen the scientific and commercial positioning of the K2VITAL platform.
  • Continued Investment in Science and Product DevelopmentManagement said Balchem will continue investing in its library of science, including research related to muscle recovery, sleep and magnesium, beauty-from-within applications such as hair, nail, and skin benefits, and additional choline applications including liver health, energy, and focus.
  • New Product Launches and PipelineBalchem launched a new encapsulated lysine product last year and rolled out the next generation of encapsulated methionine on October 1. Management also said a pipeline of additional product launches is being developed to support continued technology penetration.
  • Potential Partnerships and Marketing ExpansionManagement said partnerships in the beauty space are being explored and that Balchem is contemplating another sports partnership, potentially with a more international or global aspect. The company has been pleased with its existing NFL New York Jets and Bayern Munich women's team partnerships and expects to announce one potential new partnership within the next month or so, before the next earnings call.
  • Twenty-Nine Consecutive Quarters of Adjusted EBITDA GrowthThe third quarter marked Balchem's 29th consecutive quarter of year-over-year growth in adjusted EBITDA. Management attributed this consistency to the strength of its portfolio, the resilience of its business model, and team execution.
  • Confidence in Fourth-Quarter Year-Over-Year GrowthManagement expects the fourth quarter to be sequentially lower than the third quarter because of historic business seasonality, but remains confident in delivering healthy year-over-year growth in the fourth quarter.

DE:BL9B Earnings History

DE:BL9B earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 19, 20272026 (Q4)1.25-1.08――
Oct 23, 20262026 (Q3)1.271.301.117.74% (+0.20)
Jul 31, 20262026 (Q2)1.131.241.0418.80% (+0.20)
Apr 30, 20262026 (Q1)1.111.11110.62% (+0.11)
Feb 20, 20262025 (Q4)1.041.080.9217.48% (+0.16)
Oct 21, 20252025 (Q3)1.031.100.9220.39% (+0.19)
Jul 31, 20252025 (Q2)1.001.040.977.34% (+0.07)
Apr 24, 20252025 (Q1)0.931.000.929.71% (+0.09)
Feb 21, 20252024 (Q4)0.940.920.848.42% (+0.07)
Oct 25, 20242024 (Q3)0.990.920.92-0.96% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed